Investigator

Anna Kleczka

specialist in medical laboratory hematology · Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Department of Bone Marrow Transplantation and Oncohematology

Research Interests

AKAnna Kleczka
Papers(1)
Caffeic Acid Phenethy…
Collaborators(2)
Radosław DzikAgata Kabała-Dzik
Institutions(2)
Medical University Of…Academy of Silesia

Papers

Caffeic Acid Phenethyl Ester (CAPE) Synergistically Enhances Paclitaxel Activity in Ovarian Cancer Cells

Caffeic acid phenethyl ester (CAPE) belongs to the phenols found in propolis. It has already shown strong antiproliferative, cytotoxic and pro-apoptotic activities against head and neck cancers and against breast, colorectal, lung and leukemia cancer cells. Ovarian cancer is one of the most dangerous gynecological cancers. Its treatment involves intensive chemotherapy with platinum salts and paclitaxel (PTX). The purpose of this study was to evaluate whether the combined use of CAPE and paclitaxel increases the effectiveness of chemotherapeutic agents. The experiment was performed on three ovarian cancer lines: OV7, HTB78, and CRL1572. The effect of the tested compounds was assessed using H-E staining, a wound-healing test, MTT and the cell death detection ELISAPLUS test. The experiment proved that very low doses of PTX (10 nM) showed a cytotoxic effect against all the cell lines tested. Also, the selected doses of CAPE had a cytotoxic effect on the tested ovarian cancer cells. An increase in the cytotoxic effect was observed in the OV7 line after the simultaneous administration of 10 nM PTX and 100 µM CAPE. The increase in the cytotoxicity was dependent on the CAPE dosage (50 vs. 100 µM) and on the duration of the experiment. In the other cell lines tested, the cytotoxic effect of PTX did not increase after the CAPE administration. The administration of PTX together with CAPE increased the percentage of apoptotic cells in the tested ovarian cancer cell lines. Moreover, the simultaneous administration of PTX and CAPE enhanced the anti-migration activity of the chemotherapeutic used in this study.

15Works
1Papers
2Collaborators
Cell Line, TumorApoptosisOvarian NeoplasmsProstatic Neoplasms

Positions

2025–

specialist in medical laboratory hematology

Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch · Department of Bone Marrow Transplantation and Oncohematology

2015–

Assistant Professor

Medical University of Silesia · Department od Pathology

2023–

scientific director for hematology in POWR.07.01.00-00-0002/22 project

Krajowa Izba Diagnostów Laboratoryjnych

2020–

laboratory assistant

Vitomed · Department of Virusology

2018–

laboratory diagnostican

Samodzielny Publiczny Szpital Kliniczny im Andrzeja Mieleckiego Slaskiego Uniwersytetu Medycznego w Katowicach · Laboratorium Centralne

2014–

Junior assistant

KORLAB medical laboratories · Biochemistry/ Immunology Laboratory

Education

2023

specialization in laboratory genetics

Medical University of Silesia

2026

postgraduate studies

Jan Kochanowski University · Faculty of Medicine

2022

specialization in laboratory medical hematology

Medical University of Silesia · School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec

2022

postgraduate studies

Jagiellonian University · Faculty of Biochemistry, Biophysics and Biotechnology

2020

PhD

Medical University of Silesia · School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec

2014

MSc

Medical University of Silesia · School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec

Country

PL